Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MB-CART 2019.1 in Patients With Refractory Multiple Sclerosis (MS)
NCT07178431Phase 2Recruiting
- Sponsor
- Miltenyi Biomedicine GmbH
- Start
- Apr 2026
- Primary completion
- Aug 2030
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zamtocabtagene autoleucel in multiple sclerosis (MS), sponsored by Miltenyi Biomedicine GmbH. Primary endpoints: Safety and Tolerability at 28 days and No Evident Disease Activity-3 at 48 weeks. Started Apr 2026; status: recruiting.
02
Drugs
zamtocabtagene autoleucel
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07178431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07178431.